Aponvie® (aprepitant) manufactured by Heron Therapeutics, Inc., a commercial- stage biotechnology company, has been approved for the prevention of postoperative nausea and vomiting (PONV) in adults.

• PONV is commonly experienced after surgery and may result in increased hospital stays, prolonged recovery time, and decreased patient satisfaction.
• Administered via a single 30-second IV injection, Aponvie is the first and only IV formulation of aprepitant for PONV prevention.
• Aponvie should not be used:
  • If you are allergic to aprepitant or any of the ingredients in Aponvie
  • If you are taking pimozide
• The launch date and pricing for Aponvie are pending.